ClinicalTrials.gg
RecruitingNCT07673887Updated Nov 9, 2026

A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer

A Phase 3 interventional study of ASP2138 and Pembrolizumab in Gastric Adenocarcinoma and Gastroesophageal Junction (GEJ) Adenocarcinoma, sponsored by Astellas Pharma Global Development, Inc.. Recruiting at 12 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Astellas Pharma Global Development, Inc. (part of Astellas Pharma Inc) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.
Updated Nov 9, 2026First site in ChinaStart date moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
570
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Adenocarcinoma by Astellas Pharma Inc — 7 open to participants now, 9 under way, 4 of them phase 3. Adenocarcinoma · Astellas Pharma Inc.

Started
2026
with 2 others
Phase 3
4 of 12
2 open now
Registered
10th of 12
by date

Among the 12 studies in Adenocarcinoma by Astellas Pharma Inc, this one is one of 3 that started in 2026, is one of 4 in phase 3, and was the 10th registered.

Adenocarcinoma

620 studies on the registry are indexed under Adenocarcinoma; 148 are open to participants now.

Browse Adenocarcinoma studies →

Open to participants now

7 of the 12 studies in Adenocarcinoma by Astellas Pharma Inc are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 111 Adenocarcinoma studies recruiting now, 82 (74%) set no upper age limit and 11 (10%) stop at 75 or younger; 7 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Adenocarcinoma by Astellas Pharma Inc, or all of them as a file.
02

Study summary

Claudin 18.2 or CLDN18.2 is a protein found on cells in the digestive system. It is also found in some tumors. Researchers are looking at ways to attack CLDN18.2 to help control tumors. ASP2138 is thought to bind to CLDN18.2 and a type of immune cell called a T cell. This "tells" the immune system to attack the tumor. ASP2138 is a potential treatment for people with gastric cancer (also known as stomach cancer) or gastroesophageal junction cancer (GEJ cancer). GEJ is where the tube that carries food (esophagus) joins the stomach.

This study is for people with gastric or GEJ cancer that has spread nearby (locally advanced) and is not removable by surgery (unresectable), or has spread to other parts of the body (metastatic). It is for those whose cancer is human epidermal growth factor receptor 2 (HER2)-negative and CLDN18.2-positive. HER2-negative means the cancer does not have extra HER2 protein, so medicines that target HER2 do not work and are therefore not used. CLDN18.2-positive means people have a certain amount of CLDN18.2 proteins on their cancer cells. In this study, researchers want to learn if ASP2138 given together with standard treatments (chemotherapy and pembrolizumab) help people with HER2-negative and CLDN18.2-positive gastric or GEJ cancer. The main aim is to learn how long people who are given ASP2138 with chemotherapy and pembrolizumab live without their cancer getting worse, compared with placebo given with chemotherapy with or without pembrolizumab, and if they live for longer. Placebo looks like the study treatment but does not have any medicine in it.

The main aim of this study is to check how well ASP2138 works when given together with chemotherapy and pembrolizumab compared with placebo plus chemotherapy with or without pembrolizumab.

People aged 18 years or older with locally advanced unresectable or metastatic gastric or GEJ cancer can take part. Their tumor should be HER2-negative and CLDN18.2-positive. The study doctors will check people for any health conditions that can exclude them from taking part, interfere with the study procedures, or pose an unacceptable risk.

This is a double-blind study. That means the people and the study doctors will not know who will receive which treatment. People will be assigned to one of 2 treatment groups by chance:

Group A: People will receive ASP2138 along with chemotherapy and pembrolizumab. Group B: People will receive placebo along with chemotherapy, with or without pembrolizumab.

People will keep receiving treatment until their cancer gets worse, they have medical problems that require stopping treatment, or a study rule says they must stop. There will be regular safety checks. People will continue to have scans of their tumor until their cancer becomes worse.

03

Conditions studied

  • Gastric Adenocarcinoma
  • Gastroesophageal Junction (GEJ) Adenocarcinoma

Browse trials for

Keywords

  • Claudin (CLDN) 18.2
  • ASP2138
  • Advanced Unresectable or Metastatic Gastric Adenocarcinoma
  • Advanced Unresectable or Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has or cytologically confirmed gastric or GEJ adenocarcinoma.
  • Participant has radiographically confirmed, locally advanced unresectable or disease within 28 days prior to randomization.
  • Participant has predicted >= 12 weeks.
  • Female participant is not pregnant and at least 1 of the following conditions apply:

    • Not a women of (WOCBP)
    • WOCBP who has a negative serum pregnancy test at screening and agrees to follow the guidance from the time of through at least 9 months after the final oxaliplatin administration and 6 months after the final administration of all other study intervention. (Note: For screening, participants with elevated serum human chorionic gonadotropin (HCG) and a demonstrated nonpregnant status through additional testing are eligible.)
  • Female participant must not be breastfeeding or lactating starting at screening and throughout the period, and at least 9 months after the final oxaliplatin administration and 6 months after the final administration of all other study intervention.
  • Female participant must not donate ova starting at first administration of study intervention and throughout the investigational period, and for 9 months after the final oxaliplatin administration and 6 months after the final administration of all other study intervention.
  • Male participant must agree to use contraception with female partner(s) of childbearing potential (including breastfeeding partner) throughout the treatment period and for 6 months after the final administration of study intervention.
  • Male participant must agree to remain abstinent or use a condom with pregnant partner(s) for the duration of the pregnancy throughout the investigational period and for 6 months after the final administration of study intervention.
  • Male participant must not donate sperm during the treatment period and for 6 months after the final administration of study intervention.
  • Participant has radiologically evaluable disease (measurable and/or non measurable) according to V1.1, per investigator assessment, \<= 28 days prior to randomization. For participants with only 1 evaluable lesion and prior radiotherapy \<= 3 months before randomization, the lesion must either be outside the field of prior radiotherapy or have documented progression following radiation therapy.
  • Participant's tumor is -negative (HER2 immunohistochemistry (IHC) score 0+/1+ or HER2 IHC score 2+/in situ hybridization (ISH) negative) as determined by local or central testing.
  • Participant has provided an formalin-fixed paraffin-embedded (FFPE) tumor sample which meets the requirements of the study as specified in the laboratory manual.
  • Participant has CLDN18.2-positive tumor as determined by central testing.
  • Participant has a valid programmed death-ligand 1 () result as determined by central testing of a tumor sample.
  • Participant with known microsatellite instability-high or mismatch repair deficient status may enroll as long as their tumor expresses PD-L1 combined positive score (CPS) >= 1 as determined by central IHC testing.
  • Participant has performance status 0 to 1.
  • Participant must meet all of the criteria based on the centrally or locally analyzed laboratory tests collected within 14 days prior to randomization. In case of multiple central laboratory data within this period, the most recent data should be used (transfusion is allowed, but posttransfusion [24 hours or later following transfusion] must be >= 9 g/dL).

South Korea Specific:

  • Participant is >= 19 years of age at the time of signing informed consent.
  • Female participant is not pregnant and at least 1 of the following conditions apply:

    • Not a WOCBP
    • WOCBP who has a negative serum pregnancy test at screening and agrees to follow the contraceptive guidance from the time of informed consent through at least 15 months after the final oxaliplatin administration and 6 months after the final administration of all other study intervention. (Note: For screening, participants with elevated serum HCG) and a demonstrated nonpregnant status through additional testing are eligible.)
  • Female participant must not be breastfeeding or lactating starting at screening and throughout the investigational period, and at least 15 months after the final oxaliplatin administration and 6 months after the final administration of all other study intervention.
  • Female participant must not donate ova starting at first administration of study intervention and throughout the investigational period, and for at least 15 months after the final oxaliplatin administration and 6 months after the final administration of all other study intervention.
  • Male participant must agree to use contraception with female partner(s) of childbearing potential (including breastfeeding partner) throughout the treatment period, and for 12 months after the final oxaliplatin administration and 6 months after the final administration of all other study intervention.
  • Male participant must agree to remain abstinent or use a condom with pregnant partner(s) for the duration of the pregnancy throughout the investigational period and for 12 months after the final oxaliplatin administration and 6 months after the final administration of all other study intervention.
  • Male participant must not donate sperm during the treatment period and for 12 months after the final oxaliplatin administration and 6 months after the final administration of all other study intervention.

Japan Specific:

  • Female participant is not pregnant and at least 1 of the following conditions apply:

    • Not a WOCBP
    • WOCBP who has a negative serum pregnancy test at screening with a medical interview and agrees to follow the contraceptive guidance from the time of informed consent through at least 9 months after the final oxaliplatin administration and 6 months after the final administration of all other study intervention. (Note: For screening, participants with elevated serum HCG and a demonstrated nonpregnant status through additional testing are eligible.)

Exclusion criteria

Exclusion Criteria:

  • Participant has mixed histology or non-adenocarcinoma gastric or GEJ cancer.
  • Participant has known active central nervous system (CNS) and/or carcinomatous meningitis. Participants with previously treated may participate provided they are radiologically stable (i.e., without evidence of progression) for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of treatment for at least 14 days prior to randomization.
  • Participant has gastrointestinal (GI) perforation, fistulae, untreated gastric ulcers that would preclude the participant from study participation, or any arterial thromboembolic event within 6 months, or any significant GI bleeding or any significant venous thromboembolism within 3 months prior to randomization.
  • Participant has a complete gastric outlet syndrome or a partial gastric outlet syndrome with persistent/recurrent vomiting.
  • Participant has pre existing peripheral neuropathy > Grade 1.
  • Participant has poorly controlled hypertension.
  • Participant has significant cardiovascular disease, including any of the following:

    • Congestive heart failure (defined as Class III or IV), myocardial infarction, unstable angina, coronary angioplasty, stenting, coronary artery bypass graft, cerebrovascular accident or hypertensive crisis within 6 months prior to randomization.
    • (QTc) interval > 450 msec for male participants; QTc interval > 470 msec for female participants.
    • Documented history or family history of congenital long QT syndrome.
    • Cardiac arrhythmias requiring anti-arrhythmic medications (Exception: Participant with rate-controlled atrial fibrillation for > 1 month prior to randomization is eligible), obligate use of cardiac pacemaker, or a history of ventricular arrhythmias (i.e., sustained ventricular tachycardia, ventricular fibrillation or Torsades de Pointes).
  • Participant has a diagnosis of immunodeficiency or has been diagnosed with an disease that has required systemic treatment in past 2 years (i.e., with use of disease-modifying agents, corticosteroids or drugs). Participants that require replacement therapy (e.g., thyroxine (T4), insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) may be enrolled.
  • Participant has psychiatric illness or social situations that would preclude study compliance.
  • Participant has history of another within 3 years prior to randomization, or any evidence of residual disease from a previously diagnosed malignancy. Participants with nonmelanoma skin cancer, localized prostate cancer treated with curative intent with no evidence of progression, low-risk or very low-risk (per standard guidelines) localized prostate cancer under active surveillance/watchful waiting without intent to treat, or carcinoma in situ of any type (if complete resection was performed) are allowed.
  • Participant has history of (non-infectious) pneumonitis that required steroids, current pneumonitis, or has a history of interstitial lung disease.
  • Participant has known, existing uncontrolled coagulopathy. Concomitant treatment with medications that affect the coagulation cascade with an (INR) > 2 (e.g., vitamin K antagonists) is not allowed.
  • Participant may receive low molecular weight heparin (LMWH) (such as enoxaparin and dalteparin) and direct oral anticoagulant (DOAC) for management of deep venous thrombosis (DVT).
  • Participant has a history of bleeding diathesis or recent major bleeding events (i.e. Grade >= 2 bleeding events 28 days prior to randomization).
  • Participant has uncontrolled intercurrent illness.
  • Participant has active infection requiring systemic therapy that has not completely resolved within 7 days prior to randomization.
  • Participant is known to have (HIV) infection except for those with cluster of differentiation (CD) 4+ T cell counts >= 350 cells/microliter (µL) and no history of acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections within the past 12 months are eligible. NOTE: Screening for HIV infection should be conducted if indicated per local requirements.
  • Participant is known to have active (positive hepatitis B surface antigen [HBsAg]) or infection. Testing is required for known history of these infections or as mandated by local requirements. NOTE: Screening for these infections should be conducted if indicated per local requirements.

    • For participant who is negative for HBsAg, but hepatitis B core (HBc) antibody positive, an hepatitis B virus (HBV) DNA test will be performed and if positive the participant will be excluded.
    • Participant with positive hepatitis C virus (HCV) serology, but negative HCV RNA test results is eligible.
    • Participant treated for HCV with undetectable viral load results is eligible.
  • Participant has a known history of a positive test for tuberculosis or known active tuberculosis infection. NOTE: Screening for these infections should be conducted per local requirements.
  • Participant has known complete dihydropyrimidine dehydrogenase (DPD) deficiency (screening for DPD deficiency should be conducted per local requirements).
  • Participant has pernicious anemia or other anemias due to vitamin B12 deficiency.
  • Participant has received prior systemic chemotherapy and/or immunotherapy for locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma. However, a maximum of 1 cycle of mFOLFOX6 or CAPOX with or without immunotherapy (for those participants with CPS >= 1) is allowed to be administered prior to randomization (Note: No dose modifications are allowed for the lead-in treatment). Participants may have received either or adjuvant chemotherapy, immunotherapy, or other systemic anticancer therapies as long as they were completed at least 6 months prior to randomization and there was disease progression occurs at least 6 months after the last dose. Participant may have received treatment with herbal medications that have known antitumor activity > 28 days prior to randomization. NOTE: Participants must have recovered from all AEs due to previous therapies to \<= Grade 1 or baseline.
  • Participant has received systemic immunosuppressive therapy, including systemic corticosteroids \<= 7 days prior to randomization. Participants using a physiologic replacement dose of hydrocortisone or its equivalent (defined as up to 10 mg per day of prednisone or equivalent), receiving a single dose of systemic corticosteroids or receiving systemic corticosteroids as premedication for radiologic imaging contrast use are allowed.
  • Participant has had a major surgical procedure \<= 28 days before randomization and has not fully recovered.
  • Participant has received a CLDN18.2-targeted therapy \<= 28 days or 5 half-lives (whichever is longer) prior to randomization, or participant has experienced Grade >= 3 GI toxicity after receiving a CLDN18.2-targeted therapy.
  • Participant has received radiotherapy for locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma \<= 14 days prior to randomization and has NOT recovered from any related toxicity. A 7-day is permitted for palliative radiation (\<= 14 days duration time for radiotherapy) to non-CNS disease.
  • Participant has received prior therapy with an , anti-PD-L1 or anti-PD-L2 agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor (e.g., cytotoxic T-lymphocyte-associated protein 4 [CTLA-4], OX-40, CD137) unless received in the perioperative setting.
  • Participant received a live or within 30 days prior to randomization. NOTE: Inactivated seasonal influenza vaccines are allowed.
  • Participant has received treatment with brivudine, sorivudine or their chemically related analogues within 28 days prior to randomization or within 5 half-lives of the drug, whichever is shorter.
  • Participant has received any therapy within 28 days prior to randomization or within 5 half-lives of the investigational medicinal product (IMP), whichever is longer.
  • Participant has any condition including clinically significant disease or co-morbidity that may adversely affect the safe delivery of treatment within this study or make the participant unsuitable for study participation.
  • Participant has prior severe allergic reaction; suspected, known immediate or delayed ; or intolerance or to any study intervention.

EU Specific:

  • Participant has known complete DPD deficiency (screening for DPD deficiency should be conducted per local requirements). All participants in the EU must be tested for DPD deficiency before receiving fluoropyrimidine-based chemotherapy, in accordance with European Society for Medical Oncology and European Medicines Agency (EMA) recommendations.
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
570 participants (estimated)

Study arms

  • Experimental
    ASP2138 in combination with pembrolizumab and chemotherapy

    Participants will receive ASP2138 as a subcutaneous (SC) injection either once every two weeks (Q2W) or once every three weeks (Q3W) from cycle 1 day 1 (C1D1) followed by intravenous (IV) infusion of pembrolizumab. Participants will be treated with either ASP2138 on days 1 and 22 of each cycle if receiving capecitabine and oxaliplatin (CAPOX) treatment, and on days 1, 15 and 29 of each cycle if receiving modified 5-fluorouracil, folinic acid and oxaliplatin (mFOLFOX6) treatment until discontinuation criteria are met. For all study interventions, the treatment cycle length is 42 days.

    Drug: ASP2138 · Drug: Pembrolizumab · Drug: Oxaliplatin · Drug: Capecitabine · Drug: Folinic acid · Drug: 5-FU

  • Placebo comparator
    Placebo for ASP2138 in combination with pembrolizumab and chemotherapy

    Participants will receive placebo matching ASP2138 as a SC injection either Q2W or Q3W from C1D1 followed by IV infusion of pembrolizumab or placebo matching pembrolizumab. Participants will be treated with either placebo matching ASP2138 on days 1 and 22 of each cycle if receiving CAPOX treatment, and on days 1, 15 and 29 of each cycle if receiving mFOLFOX6 treatment until discontinuation criteria are met. For all study interventions, the treatment cycle length is 42 days.

    Drug: Pembrolizumab · Drug: Oxaliplatin · Drug: Capecitabine · Drug: Folinic acid · Drug: 5-FU · Drug: Placebo for ASP2138 · Drug: Placebo for Pembrolizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    OS is defined as the time from the date of randomization until the documented date of death from any cause.

    Time frame: Up to 54 months

  2. Progression Free Survival (PFS) per Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST V1.1) by Blinded Independent Central Review (BICR)

    PFS is defined as the time from the date of randomization until the date of radiographic disease progression per RECIST V1.1 by BICR or death from any cause, whichever is earlier.

    Time frame: Up to 54 months

Secondary outcomes

  1. Objective response rate (ORR) per RECIST V1.1 by BICR

    ORR is defined as the proportion of participants with a best overall response (BOR) of complete response (CR) or partial response (PR) based on RECIST V1.1 by BICR.

    Time frame: Up to 54 months

  2. Disease control rate (DCR) per RECIST V1.1 by BICR

    DCR is defined as the proportion of subjects with a BOR of CR, PR, or stable disease (SD) based on RECIST V1.1 by BICR.

    Time frame: Up to 54 months

  3. Duration of response (DOR) per RECIST V1.1 by BICR

    DOR is defined as the time from the date of the first response (CR/PR) until the date of disease progression as per RECIST V1.1 by BICR or date of death from any cause, whichever is earlier.

    Time frame: Up to 54 months

  4. PFS per RECIST V1.1 by investigator assessment

    PFS per investigator assessment is defined as the time from the date of randomization until the date of documented radiologic disease progression based on RECIST V1.1 by investigator assessment or until death due to any cause, whichever is earlier.

    Time frame: Up to 54 months

  5. ORR per RECIST V1.1 by investigator assessment

    ORR per investigator assessment is defined as the proportion of participants with a BOR of CR or PR based on RECIST V1.1.

    Time frame: Up to 54 months

  6. DCR per RECIST V1.1 by investigator assessment

    DCR per investigator assessment is defined as the proportion of subjects with a BOR of CR, PR, or SD based on RECIST V1.1.

    Time frame: Up to 54 months

  7. DOR per RECIST V1.1 by investigator assessment

    DOR per investigator assessment is defined as the time from the date of the first response (CR/PR) until the date of disease progression as per RECIST V1.1 or date of death from any cause, whichever is earlier.

    Time frame: Up to 54 months

  8. Number of participants with adverse events (AEs)

    An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention.

    Time frame: Up to 46 months

  9. Number of participants with serious adverse events (SAEs)

    An SAE is defined as any untoward medical occurrence that, at any dose results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, and other medically important events.

    Time frame: Up to 46 months

  10. Number of participants with potentially clinically significant vital sign changes

    Number of participants with potentially clinically significant vital sign values.

    Time frame: Up to 44 months

  11. Number of participants with laboratory value abnormalities and/or AEs

    Number of participants with potentially clinically significant laboratory values.

    Time frame: Up to 44 months

  12. Number of participants with electrocardiogram (ECG) normals, abnormalities and/or AEs

    Number of participants with potentially clinically significant ECG values.

    Time frame: Up to 44 months

  13. Number of participants at each grade of Eastern Cooperative Oncology Group (ECOG) performance status

    The ECOG scale will be used to assess performance status. Grades range from 0 (fully active) to 5 (dead). Negative change scores indicate an improvement. Positive scores indicate a decline in performance.

    Time frame: Up to 44 months

  14. Pharmacokinetics (PK): concentration immediately prior to dosing at multiple dosing (Ctrough) of ASP2138

    Ctrough will be reported from the PK serum samples collected.

    Time frame: Up to 45 months

  15. Functional Assessment of Chronic Illness Therapy-General item GP5 (FACIT-GP5) Responses Over Time

    FACIT-GP5 is a single item to measure the overall impact of treatment toxicity, based upon its association with the number and degree of AEs. The item "I am bothered by side effects of treatment," is rated on a 5-point scale ranging from "not at all" (0) to "very much" (4).

    Time frame: Up to 46 months

  16. Patient reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Responses Over Time

    PRO-CTCAE questionnaire allow participants to report on the frequency severity, and interference of the side effects they experience. Selected items from the PRO CTCAE questionnaire will be used to enhance the assessment of symptomatic AEs in the study.

    Time frame: Up to 46 Months

  17. Change from Baseline in Health-related Quality of Life (HRQoL) Measured by European Organisation for Research and Treatment of Cancer Quality of Life of Cancer Patients Core Questionnaire (EORTC QLQ-C30)

    EORTC QLQ-C30 is a cancer-specific instrument consisting of global health status/quality of life scale; 5 functional scales (physical, role, emotional, social and cognitive); 3 symptom scales (fatigue, nausea, and vomiting and pain); and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea and financial difficulties). Participants rate items on a four-point scale, with 1 as "not at all" and 4 as "very much." For functional scales, higher scores indicate better functioning, while for symptom scales/items, higher scores indicate worse symptoms.

    Time frame: Baseline and up to 46 months

  18. Change from Baseline in HRQoL measured by European Organisation for Research and Treatment of Cancer Quality of Life of Cancer Patients Oesophago-Gastric Module (EORTC QLQ OG25)

    EORTC QLQ-OG25 questionnaire is a 25-item instrument that evaluates gastric and GEJ cancer-specific symptoms. This module consists of 6 scales: dysphagia (3 items), eating restrictions (4 items), reflux (2 items), odynophagia (2 items), pain and discomfort (2 items) and anxiety (2 items), as well as 10 single items: eating in front of others, dry mouth, trouble with taste, body image, trouble swallowing saliva, choked when swallowing, trouble with coughing, trouble talking, weight loss and hair loss. Each item is scored on a scale of 1 (Not at all) to 4 (Very much). Individual item scores are transformed to a 0 (no symptoms) to 100 (maximum symptom burden) scale

    Time frame: Baseline and up to 46 months

  19. Change from Baseline in HRQoL measured by EQ-5D, 5-Level Questionnaire (EQ-5D-5L)

    EQ-5D-5L is a standardized instrument for use as a measure of health outcome consisting of 6 items that cover 5 main scales (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) and a general visual analog scale for health status. Each item is scored on a scale of 1 (no problem or none) to 5 (unable to perform activity). The VAS ranges from 0 (worst health status) and 100 (best health status).

    Time frame: Baseline and up to 46 months

  20. Number of participants with anti-drug antibodies-positive against ASP2138

    Number of participants with anti-drug antibodies-positive will be reported.

    Time frame: Up to 45 months

07

Study locations

12 of 12 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as compounds terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.

Access criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.

Data sharing details ↗ · www.clinicaltrials.astellas.com

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Feb 2031, 55 months after the start.

Of 26 phase 3 interventional studies under Adenocarcinoma, half reached primary completion within 91 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 101. This study's planned 55 months is below that.

Start moved once since we started tracking on Sep 25, 2026: Jun 2026 → Jul 2026, on Oct 20, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2026
First posted
Jun 29, 2026
StartActual
Jul 28, 2026was Jun 2026
Primary completionEst.
Feb 28, 2031
CompletionEst.
Feb 28, 2031
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
9 sites added — first site in China
Show 9 added (7 Japan, 2 China)
  • National Cancer Center Hospital · Chuo-ku, Japan
  • Sun Yat-Sen University Cancer Center - Huangpu Campus · Guangzhou, China
  • Sun Yat-sen University Cancer · Guangzhou, China
  • National Cancer Center Hospital East · Kashiwa, Japan
  • The Cancer Institute Hospital of JFCR · Koto-ku, Japan
  • National Hospital Organization Shikoku Cancer Center · Matsuyama, Japan
  • National Hospital Organization Hokkaido Cancer Center · Sapporo, Japan
  • Hyogo Cancer Center · Akashi, Japan
  • Osaka International Cancer Institute · Osaka, Japan
across 3 updates, Oct 20, 2026 – Nov 9, 2026
Start date
Jun 30, 2026→Jul 28, 2026
Oct 20, 2026
Show all 3 updates
  1. Nov 9, 2026
    4 sites added
    Show 4 added (4 Japan)
    • National Hospital Organization Shikoku Cancer Center · Matsuyama, Japan
    • National Hospital Organization Hokkaido Cancer Center · Sapporo, Japan
    • Hyogo Cancer Center · Akashi, Japan
    • Osaka International Cancer Institute · Osaka, Japan
    + 1 other change: verification date
  2. Oct 22, 2026
    4 sites added — first site in China
    Show 4 added (2 China, 2 Japan)
    • Sun Yat-Sen University Cancer Center - Huangpu Campus · Guangzhou, China
    • Sun Yat-sen University Cancer · Guangzhou, China
    • National Cancer Center Hospital East · Kashiwa, Japan
    • The Cancer Institute Hospital of JFCR · Koto-ku, Japan
  3. Oct 20, 2026
    1 site added
    Show site
    • National Cancer Center Hospital · Chuo-ku, Japan
    Start date Jun 30, 2026→Jul 28, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07673887
Responsible party
Sponsor
First posted
Jun 29, 2026
Start date
Jul 28, 2026
Primary completion
Feb 28, 2031 (estimated)
Completion
Feb 28, 2031 (estimated)
Last update
Nov 9, 2026

Study contacts

Astellas Pharma Global Development Inc
Contact
Astellas.registration@astellas.com
800-888-7704
Development Physician
study director · Astellas Pharma Global Development, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Emaretamig

Start the discussion